Cyclacel Pharmaceuticals, Inc. (CYCC)

5d ago, source: Yahoo Finance

- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J ...

Cyclacel Pharmaceuticals Inc. (UXI.SG)

2mon ago, source: Yahoo Finance

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced ...

Cyclacel Pharmaceuticals Inc. 6% Conv. Pfd.

19d ago, source: Wall Street Journal

1 Day CYCCP -1.70% DJIA 0.80% Russell 2K 0.47% Health Care/Life Sciences 1.40% ...

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

1mon ago, source: Stockhouse

BERKELEY HEIGHTS, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative ...

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

1mon ago, source: ADVFN

The webcast will be archived for 90 days and the audio replay for 7 days. About Cyclacel Pharmaceuticals, Inc. Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer ...

Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

1mon ago, source: Stockhouse

BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative ...

Cyclacel Pharmaceuticals Inc CYCC

1mon ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Cyclacel Pharmaceuticals Inc.

26d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...